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Drug delivery systems involve technology designed to maximize therapeutic efficacy 
of drugs by controlling their biodistribution profile. In order to optimize a function 
of the delivery systems, their biodistribution characteristics should be 
systematically understood. Pharmacokinetic analysis based on the clearance 
concepts provides quantitative information of the biodistribution, which can be 
related to physicochemical properties of the delivery system. Various delivery 
systems including macromolecular drug conjugates, chemically or genetically 
modified proteins, and particulate drug carriers have been designed and developed 
so far. In this article, we review physiological and pharmacokinetic implications of 
the delivery systems. 
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In vivo fate of a drug following administration is determined by its 
physicochemical (e.g., passive diffusion) and biochemical (e.g., interactions with 
metabolizing enzymes and transporters) properties, in addition to biophysical 
properties of the body. Since drugs are not usually endogenous substances that play 
important roles in maintaining homeostasis of the body, they are not provided by 
the biological system with an appropriate biodistribution profile. In other words, 
pharmacokinetics of a drug is not necessarily optimized to exhibit its 
pharmacological actions. Lack of selectivity in biodistribution sometimes leads to 
unwanted side effects, particularly for anti-cancer drugs that have severe 
cytotoxicity. In order to ensure safety and efficacy, drugs are required to be delivered 
to their target site selectively at an optimal rate. 
Drug delivery system involves technology designed to maximize therapeutic 
efficacy of drugs by controlling their biodistribution profile. To offer such a function, 
the delivery system itself is required to have an optimal selectivity and specificity 
towards the target tissues or cells. A number of techniques intended for targeted 
drug delivery have been proposed and developed so far, being classified roughly into 
macromolecular and particulate drug carriers. The biodistribution profiles of carrier 
systems are determined by their physicochemical and biochemical properties, 
similarly to the case of drugs. To clarify qualitative and quantitative relationships of 
these properties with pharmacokinetics is important in developing new carrier 
systems suitable for targeted drug delivery. Physiologically-based pharmacokinetics 
(PBPK) modeling that was proposed first by Bischoff and Dedrick [1; 2] in the late 
60’s is a powerful tool for understanding the pharmacokinetic profile of drugs 
mechanistically. In addition, the introduction of clearance concepts, where clearance 
in drug elimination organ is derived from the blood flow and the intrinsic ability of 
the organ to eliminate a drug, clarified the physiological interpretation of drug 
elimination [3]. The PBPK modeling approach is also available for evaluating 
pharmacokinetic profiles of drug delivery system [4; 5]. 
By linking pharmacokinetic evaluations with physicochemical properties of 
the systems, various factors influencing their biodistribution have been clarified so 
far. This article aims to review physiological and pharmacokinetic implications of 






2. Clearance analysis for tissue distribution of drug carriers 
 
Since mass transfer is a probabilistic event, it is proportional to the 
concentration (or mass) of the substance. Taken together with that, the mass 
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where Xi and Cp represent the amount of a substance in tissue and its concentration 
in plasma, respectively; and CLapp,i and kelim represent apparent tissue uptake 
clearance and elimination rate constant, respectively. At an initial time phase, the 
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In other words, by analyzing the data at earlier time points, tissue uptake 
characteristics of the substance can be estimated. 
An appropriate selection of tracer agents can ensure the approximation. 
Generally, macromolecular and particulate carriers are likely to undergo 
degradation following cellular uptake. When traced with radioisotopes, the presence 
of radioactive degradation fragments may interfere with the evaluation of 
distribution kinetics of an intact carrier system. Therefore, radiolabeling with 111In 
is preferred for biodistribution studies for protein drugs and plasmid DNA, because 
the metabolite 111In-chelate complex is trapped in the cells due to its plasma 
membrane-impermeability [6]. 
Integration of Eq. 2 gives: 
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where AUCp,0-t represents the area under the plasma concentration-time curve. 
Plasma concentration-time profile can be expressed as a function of one or more 
exponentials in many cases. Then, the AUCp,0-t values at any time point can be 
calculated by fitting an equation to the experimental data using a least-squares 
method. According to Eq. 3, CLapp,i can be estimated from the slope of regression for 
AUCp,0-t vs Xi(t) relationship. 
 




The clearance concept allows us to assess an absolute efficiency of mass 
transfer. Since tissue uptake or urinary excretion processes are in parallel, the 
amount in tissue or eliminated depends on a balance of the entire processes. 
Therefore, the amount in tissue or eliminated cannot simply be referred to as the 
measure of mass transfer. The rate of transport can be normalized as clearance, 
under the assumption that mass transfer occurs from the blood or plasma. 
Therefore, clearance depicts mutually independent tissue uptake rate. To compare 
disposition characteristics of drug delivery systems directly and systematically, 
application of the clearance concept is necessary. Figure 1 shows a scatter plot of 
hepatic uptake versus urinary excretion clearances for various macromolecules and 
proteins. As it will be discussed later, the clearance analysis helps us to understand 




3. Prolongation of retention time in blood 
 
Prolonged retention time in blood provides drugs with a chance to distribute to 
their target tissue/organ, leading to an increase in duration of their pharmacological 
activities. Glomerular filtration and hepatic uptake of drug carriers should be 
avoided, as long as neither kidney nor liver is a drug target. 
 
 
3.1. Reduction of glomerular filtration 
 
3.1.1. Physicochemical properties determining glomerular filtration 
 
There are numerous pores, called as fenestrae, in the glomerular endothelium. 
Since the diameter of the fenestrae is as large as 70-90 nm [7; 8], macromolecules 
freely pass through the endothelium. Therefore, the rate of glomerular filtration is 
rather limited by transport across basement membranes which support glomerular 
endothelial cells. According to electron tomography studies, the glomerular 
slit-pores are 35 Å (3.5 nm) in diameter [9]. It is limited for molecules of the size of 
albumin (about 80×80×30 Å) to pass through these pores [9]. However, it has been 
reported that quantum dots with a final hydrodynamic diameter of smaller than 5.5 
nm (e.g., 4.99 and 4.36 nm) are rapidly excreted into urine [10]. It is in good 
 7 
 
agreement with a general finding that macromolecules with a molecular weight of 
<50,000 (approximately 6 nm in diameter) are susceptible to glomerular filtration 
[4]. In fact, dextran with the molecular weight of 70kDa has a 50-times less urinary 
excretion clearance than that of 10kDa dextran (Figure 1). Charge of 
macromolecules is another determinant of glomerular filtration. Since the basement 
membrane of glomerulus is mainly comprised of glycosaminoglycans, negatively 
charged polysaccharides, it also exhibits permselectivity towards charged 
macromolecules [7; 8]. Positively charged macromolecules are filtered more 
effectively than anionic macromolecules. cationization with diethylaminoethyl 
group (DEADex) increases the urinary excretion of 70kDa dextran, whilst 
anionization with carboxymethyl group (CMDex) decreases it (Figure 1). Urinary 
clearance of bovine serum albumin (67kDa) is much lower than 70kDa dextran and 
CMDex, in spite of a similar molecular size. It is attributed to involvement of 
specialized endocytic reabsorption mechanisms [11; 12].  
 
 
3.1.2. Prolonged blood retention of therapeutic proteins by chemically or genetically 
modification 
 
Clinical application of protein drugs is often limited by their short biological 
half-lives [13]. Various factors are involved in rapid elimination of proteins, 
including proteolytic degradation, reticuloendothelial uptake, and 
receptor-mediated clearance. Glomerular filtration is a major problem for many 
therapeutic proteins. Conjugation with biocompatible polymers is a simple and 
effective way to reduce glomerular filtration of protein drugs and subsequently 
prolong their blood circulation time. Polyethylene glycol is the most popular 
macromolecular modifier for this purposes, as represented by pegylated interferon  
(PEG-IFN) [14] and granulocyte colony-stimulating factor (PEG-GCSF) [15]. In 
addition, pegylation of proteins can reduce their hepatic uptake. Catalase (235 kDa), 
one of anti-oxidant enzymes, is known to be rapidly taken up by the liver, mainly by 
the hepatocytes [16]. Pegylation of catalase reduced total body clearance by 67 times 
(34,900 and 520 µL/h for native catalase and PEG-catalase, respectively) [16]. The 
total body clearance of PEG-catalase is on the same order of that of BSA (131 µL/h) 
and dextran (685 µL/h). Prolonged retention of catalase in plasma resulted in 
augmented inhibitory effects on tumor metastasis [17; 18; 19] and diabetes [20]. 
However, it expectedly hampered a protective effect of catalase on reactive oxygen 
 8 
 
species (ROS)-mediated liver injury, due to reduction of hepatic uptake [16]. As it 
will be described later, catalase must be delivered to liver non-parenchymal cells to 
weaken ROS-mediated liver injury. 
Introduction of lipophilic moieties to the proteins prolongs their plasma 
half-life due to binding to plasma proteins or blood cells. A typical example is 
SMANCS, which is poly(styrene–co–maleic acid/half-n-butyl ester) (SMA) 
conjugated with neocarzinostatin (NCS) [21; 22]. In spite of the molecular size being 
16 kDa, SMANCS is bound to albumin and apparently exhibits a molecular size of 
~80 kDa which is large enough to escape from glomerular filtration. Lecithinized 
SOD is another example of prolongation of the plasma half-life [23; 24; 25]. It 
possesses a high affinity to plasma membrane components and promiscuously binds 
to blood and endothelial cells [23]. Another method to prolong the plasma half-life 
and pharmacological activity is to genetically fuse therapeutic peptide/protein drugs 
with albumin. Successful examples include glucagon-like peptide 1 [26], interferon 
alfa-2b [27], thioredoxin [28], and single chain diabodies [29]. Fusion protein 
technologies have also been used for active targeting, which includes RGD 
peptide-fused endostatin [30] and tumor necrosis factor–related apoptosis-inducing 
ligand (TRAIL) [31] for targeted delivery to the tumor neovasculature. 
 
 
3.2. Reduction of reticuloendothelial uptake 
 
The reticuloendothelial system (RES) is a part of the immune system, 
comprised of phagocytic cells in different organs of the body. Phagocytic cells are 
capable of engulfing microorganisms and foreign substances that may cause harm 
to the body. Particulate drug carriers are required to escape from 
reticuloendothelial uptake for long-term retention in the systemic circulation. 
 
3.2.1. Complement activation by drug carriers 
 
Phagocytosis of particulate drug carriers is accelerated by association with 
complements and immunoglobulins [32; 33]. There are three pathways of 
complement activation: i.e., classical pathway, alternative pathway, and lectin 
pathway. The classical pathway starts binding of C1q to antigen-bound IgG or IgM, 
followed by C1 complex formation and activation of C2-C9 components. Even in the 
absence of immunoglobulins, C1q can bind via its collagen-like stalks to a variety of 
 9 
 
substances including proteins, polyanions, DNA, and anionic liposomes. The 
alternative pathway started with C3 components without involving the binding C1, 
which is mainly activated by complex polysaccharides and lipopolysaccharides. In 
the lectin pathway, the complement is activated by a serum protein, called mannan 
(mannose)-binding protein (MBP) or mannan (mannose)-binding lectin (MBL), 
which is able to bind particular carbohydrates, such as D-mannose, L-fucose, and 
N-acetylglucosamine, on the surface of microorganisms. MBP is known to bind to 
and accelerate phagocytosis of mannosylated liposomes [34; 35].  
On the other hand, serum albumin might partially protect nanoparticles from 
being opsonized, based on the finding that pre-incubation of polystyrene 
nanoparticles with serum albumin reduces their clearance from blood [36]. It has 
also been known that particulate carrier systems such as liposomes [37; 38] and 
polystyrene microspheres [39; 40] are associated with serum albumin in a 
nonspecific manner. However, it should be noted that, unless polystyrene 
nanoparticles were pre-incubated with serum albumin, the total body clearance of 
the particles was 4-5 times higher [36]. The total body clearance of polystyrene 
nanoparticles is as high as to correspond to the single-pass hepatic extraction of 
approximately 40 %. Thus, the protective effect of serum albumin would be limited 
under in vivo condition, even though a high concentration (~4 g/dL) of serum 
albumin is present in serum. 
 
 
3.2.2. Physicochemical properties determining phagocytosis of particulate drug 
carriers 
 
Particulate drug carriers are nano-sized assemblies that are stably dispersed 
by the help of amphipathic ingredients. They are primarily divided into 
lipid/surfactant-based (liposomes and emulsions) and polymer-based (polymeric 
nanospheres and micelles). Formulation characteristics such as structural integrity, 
sustainability, drug-holding capacity depends largely on the structural 
characteristics of the particulate carriers. However, overall pharmacokinetic 
behavior appears to be rather influenced by macroscopic characteristics of the 
particulate carriers such as the size and surface properties. 
Particle size is a key parameter affecting phagocytic uptake of particulate 
carriers. For various polymer particles, higher phagocytic uptake has been observed 
when their size increases from around 200 nm to several microns [41]. This might 
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be related to opsonization of the particles. Adsorption of opsonins is known to be 
lower for smaller particles [39; 42; 43], presumably due to geometrical problems in 
efficient arrangement of complements on their highly curved surface structure [44]. 
Surface properties such as charge and hydrophobicity are critical in 
determining interactions of particulate carriers with biological components. It has 
been known for a long time that negatively charged liposomes containing certain 
anionic lipids such as phosphatidylserine, phosphatidylglycerol, and phosphatidic 
acid are rapidly taken up by macrophages [38; 45; 46]. Although involvement of 
scavenger receptors is controversial [47; 48], activation of the complement system is 
responsible for hepatic clearance of anionic liposomes [38; 49]. Hydrophobicity also 
plays an important role in biodistribution of particulate carriers. Serum proteins 
including IgG and other opsonins have high affinities to the hydrophobic surface of 
particles [50]. Coating with lecithins has been shown to significantly reduce hepatic 




3.2.3. Prolonged blood retention of particulate drug carriers 
 
It has been well-known for many years that particulate drug carriers are 
rapidly taken up by the RES, including liposomes [45; 52] and microspheres [53; 54]. 
For example, hepatic uptake clearance of polystyrene microspheres with a particle 
size of 500 nm have been estimated to be 7.6 mL/min in rats [39], which indicates 
that approximately a half of microspheres flowing into the liver is taken up by the 
liver. However, grafting hydrophilic polymers onto particulate carriers can sterically 
hinder interaction of the particle cores with opsonins and cell membranes. Among 
hydrophilic polymers, polyethylene glycol (PEG) has been most extensively used for 
this purpose [41; 55]. Lipid nanoparticles including liposomes can be pegylated by 
anchoring PEG-phospholipids or PEG-lipids. Pegylation of polymeric nanoparticles 
can be achieved by adhering surfactants like poloxamers or polysorbates onto 
nanoparticles, or by formulating nanoparticles with copolymers comprising PEG 
and a biodegradable moiety. Due to the highly flexible, well-hydrated nature of PEG 
chains, the PEG layer forms a water cloud, i.e., a considerable exclusion volume [44]. 
The water cloud represents a minimal interfacial free energy, leading to reduction 
in attraction force towards environmental proteins including opsonins. In fact, a 
number of studies have demonstrated that pegylation of particulate carriers results 
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in dramatically reduced RES uptake and prolonged circulation half-life. 
The second dose of pegylated liposomes after several days interval exhibits a 
significantly faster clearance from blood as compared to the first dose, being 
referred to as the “accelerated blood clearance (ABC) phenomenon” [56; 57; 58]. It is 
attributed to production of anti-PEG IgM from spleen in response to an injected 
dose of pegylated liposomes. Anti-PEG IgM leads to opsonization of a second dose of 
pegylated liposomes by C3 fragments and enhanced uptake by the Kupffer cells in 
liver. This phenomenon is observed with “empty” pegylated liposomes, but not with 
doxorubicin-containing liposomes since doxorubicin inhibits the proliferation of B 
cells in the spleen [59]. Regarding drugs other than antiproliferative agents (e.g., 
nucleic acids), caution should be paid to the ABC phenomenon [60].  
 
 
4. Enhanced permeability retention (EPR) effect for tumor drug targeting 
 
In a wide range of disorders such as solid tumors and inflammation tissues, 
pathological angiogenesis occurs. Abnormal microvascular proliferation results in 
production of immature and fragile blood vessels. Various vascular mediators such 
as bradykinin, nitric oxide, and prostaglandins induce extensive vascular 
permeability [22]. Passive targeting is a localized drug delivery technique to exploit 
pathophysiological vascular architecture of tumors and inflammation tissues. In 
comparison to the normal tissues, tumor microvascular endothelium exhibits 
elevated permeability to macromolecules. Along with lack of lymphatic drainage, 
extravasated macromolecules accumulate in tumor tissues for long periods. This is 




The first demonstration of the EPR effect was done with SMANCS/Lipiodol 
[21; 22]. When SMANCS/Lipiodol is infused intraarterially, a significantly high 
tumor/blood ratio of the drug can be obtained. Thereafter, the EPR effect has been 
observed with various polymer conjugates such as dextran [61; 62], albumin [63; 64], 
poly(hydroxypropylmethacrylamide) (HPMA) copolymer [65; 66], polyethylene 
glycol [67; 68], and polyvinyl alcohol [69]. Although they are mostly investigated in 
rodents, PK1 (HPMA-doxorubicin conjugate) has been shown to achieve response 
rates of 21% and 11.5% in patients with metastatic breast and lung cancer, 
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respectively [70]. Although not polymer conjugates, Doxil, which is a pegylated 
liposome that encapsulates doxorubicin, was approved for the treatment of Kaposi 
sarcoma and late stage ovarian cancer. Abraxane is a paclitaxel nanoparticle 
consisting of strongly albumin-bound paclitaxel, which is intended for metastatic 
breast cancer. 
Although several commercial products exploiting the EPR effect have already 
been launched, it have been pointed out that translational research in EPR-based 
medicines is too slow [71]. Possible reasons raised were dilemmas in uptake and 
drug release, substantially low targeting efficiency, validity of animal models, and 
biological diversity of tumors [71]. Stealth properties of the nanocarriers are not 
exceptional for target tumor cells; that is, their hydrophilic shells prevent 
interaction with tumor cells as well as do so with opsonins and phagocytes. A 
similar dilemma exists in drug release. If active drugs were stably associated or 
conjugated with carriers, drug release would be slow in both the systemic 
circulation and the target tissue. In tumor tissues, convective transport is limited 
due to high internal fluid pressure [72]. Therefore, it is ideal that active drugs, 
having higher diffusivity than drug carriers, are efficiently released once the 
carriers reach tumor tissues. To solve these problems, target-site specific 
machineries for drug release might have to be implemented in carrier systems [73; 
74]. Another point raised is that, with success of EPR-based targeting, 
accumulation of active drug inside the tumor rarely exceeds 5% of the injected dose 
[71; 75]. However, the tumor/blood (T/B) concentration ratio would rather be an 
important measure from the pharmacokinetic/pharmacodynamic point of view, 
since concentration (but not amount) of active drug determines intensity of 
pharmacological and toxicological response. The most critical point appears to be 
difference in the progression rate of tumors between animal models and human 
patients. The authors cautioned that the EPR effect is emphasized in animal 




5. Control of drug release from polymer conjugates 
 
Prodrug linkers have been designed to effectively release a parent drug at the 
target site. Commonly used linkers include ester, amide, disulfide, and 
imine/hydrazone [76]. Ester bonds are the most common linkages in prodrug design, 
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since carboxy and hydroxy groups are available in most parent drugs. The ester 
bonds would often be inappropriate because they can easily be hydrolyzed by 
esterase ubiquitously distributed in the body. Amide bonds, which are another 
commonly used linkage, exhibit relatively higher enzyme stability than ester bonds. 
Target-specific drug release can be achieved by paying attention to physiological 
and biochemical differences between target and non-target tissues. The differences 
include expression of specific enzymes, interstitial or intracellular pH, and redox 
balance [73; 74].  
Peptide linkers are cleaved selectively by tissue-specific enzymes and liberate 
the parent drug at the target site [77; 78; 79]. Lysosomal cysteine proteases such as 
cathepsin B are overexpressed in tumor cells [80]. In the study of lysosomotropic 
modified dextran-doxorubicin conjugates, the concentration of liberated doxorubicin 
in the tumor was gradually increased over 48 h following intravenous injection, 
whereas that in the plasma was negligibly small [79]. When two 
dextran-doxorubicin conjugates having GGFG and GGIG peptide linkers were 
compared, in vitro release rate of liberated doxorubicin from the conjugates in 
tumor cell homogenates was 10-fold different, whilst in vivo concentration profiles 
for liberated doxorubicin, as well as those for the conjugates, were similar in both 
conjugates after intravenous injection [79]. The in vitro-in vivo discrepancy can be 
explained by assuming that uptake of the conjugates by tumor cell is much slower 
than release of doxorubicin from the conjugates. It has also been demonstrated that 
both conjugates showed significant anti-tumor activity in tumor-bearing mice but 
the conjugate having GGPG linker did not [79]. Peptide linkers sensitive to matrix 
metalloprotease-2 (MMP-2) and MMP-9 were also found to be effective for 
tumoritropic drug delivery. Dextran-methotrexate conjugate with the PVGLIG 
linker was much less toxic in the small intestine and bone marrow than that with a 
MMP-insensitive GIVGPL linker, while both conjugates significantly inhibited 
tumor growth [62]. The hydrazone bond is relatively stable at neutral pH, but it 
undergoes hydrolysis at acidic pH (pH4.5-6.5). Therefore, macromolecular prodrugs 
with such an acid-cleavable linker can release the parent drug in endosomal 
compartments following internalization into the cell interior. Prostaglandin E1 
covalently bonded to lactosylated poly(L-glutamic hydrazide) is efficiently released 
after internalization into hepatocytes, and exhibits a significant anti-inflammatory 
effect in mice with fulminant hepatitis [81]. Various acid-cleavable linkers have 
been introduced to be available for site-specific drug release in tumors [82] and 
rheumatoid arthritis [83]. Generally, cleavage rate and sensitivity of 
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acid-responsive linkers are variable for each conjugate, and in some cases cleavage 
at the site other than hydrazine bond occurs [84; 85]. Since the cleavage rate of 
linkers is critical in therapeutic efficacy of conjugates, the linkers need to be 
carefully designed and evaluated. 
 
 
6. Acceleration of delivery of drugs to organs and tissues 
 
6.1. Enhanced delivery by cationization 
 
Alteration of net charge by chemical modification is also an effective approach 
for targeted delivery of protein drugs (Figure 1). It is known that 
large-molecular-weight, cationic macromolecules tend to accumulate rapidly in the 
liver [61; 86], even though they might interact with blood components. The liver 
sinusoids possess a number of fenestrae with mean diameter of approximately 100 
nm and lack a diaphragm and a basal lamina underneath the endothelium. Due to 
the specialized vascular structure, macromolecules are freely accessible to 
parenchymal cells. Therefore, cationic macromolecules are rapidly taken up by the 
liver, primarily hepatocytes, via electrostatic interaction with negatively charged 
cell surfaces. Although slower than that observed in receptor-mediated endocytosis, 
massive internalization of the proteins into the cell interior occurs by absorptive 
endocytosis [86]. Hepatic targeting of cationic derivatives of dextran bearing 
mitomycin C [61] and superoxide dismutase [87] has been reported. 
On the other hand, cationic molecules that are small enough to undergo 
glomerular filtration can be taken up by the kidney not only from the capillary side 
but from the luminal side. Superoxide dismutase cationized within such an extent 
that the loss of activity is acceptable is taken up by the kidney more effectively than 
native superoxide dismutase [88]. It exhibits much greater therapeutic potency 
against kidney ischemia/reperfusion injury in rats [89]. 
 
 
6.2. Receptor-mediated delivery of therapeutic proteins 
 
Glycoconjugates have been extensively studied for active targeting of protein 
drugs to specific cell types. Liver parenchymal cells, i.e., hepatocytes, express 
exclusively asialoglycoprotein receptors, which recognize galactose terminal 
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residues of glycoproteins. Although the targeting efficiency depends on the 
molecular size of a protein drug and the number of galactose moieties conjugated 
[90; 91], galactosylated proteins are almost completely delivered to hepatocytes. The 
hepatic uptake clearances for galactosylated proteins are almost the same as 
hepatic plasma flow [90; 91], indicating that the uptake rates by hepatocytes are 
much higher than the hepatic plasma flow. Conjugation with mannose or fucose 
enables delivery of the protein to antigen-presenting cells, e.g., macrophages and 
dendritic cells, expressing specialized receptors [16; 92; 93; 94]. When mannosylated 
and fucosylated proteins are injected intravenously, they also rapidly distribute to 
the liver but to different cell types than galactosylated proteins. Mannosylated 
bovine serum albumin (Man-BSA) is taken up by liver endothelial cells and Kupffer 
cells, and fucosylated BSA is taken up more specifically by Kupffer cells [95]. 
Kupffer cells, which are the resident macrophages of the liver, produce ROS and 
release lysosomal enzymes by various pathophysiological stimuli including 
ischemia-reperfusion and septic shock. Mannosylated and fucosylated catalase 
following intravenous injection were found to be effective for these ROS-mediated 
injuries [16; 92; 93; 94]. 
Highly negatively charged molecules are recognized by scavenger receptors 
expressed on a variety of cells including macrophages, Kupffer cells, and sinusoidal 
endothelial cells. Proteins modified with maleic acid or succinic acid are ligands for 
the scavenger receptors, which are also rapidly taken up by the liver [93; 94; 96]. A 
physiological pharmacokinetic model, involving a saturable process with 
Michaelis-Menten kinetics, revealed that the surface density of negative charges 
was correlated with the affinity of succinylated proteins for the hepatic scavenger 
receptors [96]. These results also provide a caution towards chemical modification of 
proteins. The amino group of lysine residue is the first choice for chemical 
modification. Reaction at the amino group usually reduces a positive charge or 
increases net negative charge of proteins. In fact, conjugation of 
para-aminophenyl-mannopyranoside to albumin with thiophosgen increased net 
negative charge with an increase in sugar density, resulting in greater affinity to 
scavenger receptor than to mannose receptor [97]. When lysine residues are 
modified, the ratio of modification should be minimal or the modification method 
that leaves unchanged net charge of a protein molecule should be selected. 
 
 




Receptor-mediated endocytic pathways have been exploited for cell-specific 
delivery of particulate carriers. Due to their sufficient size, particulate carriers have 
the potential of being modified with a variety of functional molecules ranging from 
small organic molecules to proteins. Representative proteins intended as a 
targeting ligand includes transferrin [98; 99], asialoglycoproteins [100], 
apolipoproteins [101], and antibodies [102]. Homing peptides, including synthetic 
peptides identified by phage display or other screening techniques, have also been 
used as a targeting ligand [103]. The advantages of using peptides instead of 
proteins include more reproducible preparations and lower immunogenicity. 
Carbohydrates [104; 105] and nucleic acids (i.e., aptamers) [106; 107] have also been 
exploited for targeted drug delivery of particulate carriers. Two transferrin-modified 
nanoparticles, i.e., CALAA-01 (cyclodextrin polymer-based nanoparticles containing 
ribonucleotide reductase siRNA) [108] and MBP-426 (liposomes containing 
oxaliplatin) [109], are now under clinical trials for the treatment of malignant 
tumors.  
Efficiency of active targeting with particulate carriers depends on biophysical 
interactions at different layers. At the level of the particle-membrane interface, 
specific (ligand-receptor) and nonspecific interactions must decrease the free energy 
at the contact site to overcome the resistive forces that hinder particle uptake (e.g., 
stretching and elasticity of cell membrane) [110]. Mathematical models to describe 
the thermodynamics of receptor-mediated endocytosis have been proposed, which 
consider specific and nonspecific interactions, diffusion of the receptors in 
membrane, and elastic bending of the membrane [111; 112]. The models can relate 
endocytic performance of nanoparticles to the particle size, the ligand density, etc. 
Although the exact mechanism remains unclear, it has been known that two 
galactosylated liposomes that contain the same amount of galactosylated 
cholesterol derivative but vary in the ratio of distearoylphosphatidylcholine and 
cholesterol exhibit different internalization rates in HepG2 cells [113]. Biophysical 
characteristics of the liposome carriers, e.g., elasticity and fluidity, would be an 
important factor in determining cellular uptake. Effect of ligand density on cellular 
uptake has been investigated with galactosylated liposomes [114]. In vitro cellular 
uptake of the galactosylated liposomes was not changed up to 2.5 mol% galactolipid, 
but increased linearly from 2.5 to 7.5 mol% (the highest tested).  
At the organ/tissue level, effect of physiological parameters such as the blood 
flow must be considered. If the intrinsic capacity of receptor-mediated uptake is 
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sufficiently high, the delivery rate becomes equal to the blood flow. In fact, in vivo 
pharmacokinetic analysis has demonstrated that hepatic uptake clearance of the 
galactosylated liposomes containing 5.0 mol% or higher galactolipid is almost the 
same as the hepatic blood flow. It should also be noted that the ligand-receptor 
interaction is a saturable process. In vivo hepatic uptake clearance of galactosylated 
liposomes decreases at a higher dose [115]. This means that the rate-limiting step in 
the hepatic uptake changes from the blood flow to the intrinsic uptake clearance 
due to the saturation of the ligand-receptor interaction. Moreover, at a high dose, 
the galactosylated liposomes are taken up by non-parenchymal cells rather than by 
hepatocytes, and can inhibit the uptake of mannosylated and fucosylated liposomes 
[115]. This indicates that contribution of the low-affinity high-capacity pathway is 
not negligible under saturation of the main pathway.  
 
 
6.4. Pharmacokinetic considerations of receptor-mediated drug delivery 
 
Receptor-mediated drug targeting to the liver is relatively easier than to other 
organs and tissues. Ligand-receptor interactions are possible only when the two 
components are in close proximity (<0.5nm) [75]. Due to unique vascular structures 
of the liver, drug carriers are freely accessible to all cell types in the liver. Therefore, 
overall probability for a ligand-bearing drug carrier to be taken up by the receptor is 
much higher for the liver than for the tissues where the blood flow is poor and 
vascular permeability of the carrier is restricted. 
Figure 3 represents overall probability for carriers to be taken up into the cell 
interior. The total process for movement from the systemic blood vessel to the cell 
interior consists of kinetic steps connected in a serial manner. According to a 




































































where Qout,i, Pin,i, Pout,i, and Uin,i are blood flow rate, influx permeability across 
endothelium, efflux permeability across endothelium, and intrinsic clearance for 
cellular uptake, respectively. As endothelial permeability (Pout,i) is higher, Ei is more 
sensitive to Ui. Since endothelial permeability is sufficiently high in the liver, 
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benefits of exploiting receptor-mediated uptake mechanism for enhanced drug 
delivery is more pronounced than in other organs. This is the reason why delivery 
directed to hepatocytes using specific ligands is effective. If the receptor-mediated 
uptake is also high enough, the Ei becomes unity, suggesting that the blood flow is 
rate-limiting. 
How about application of active targeting techniques to tumor targeting? 
There are several reviews dealing with this topic [75; 116; 117], but we are going to 
explain it from the pharmacokinetic point of view. It is meaningful at least to take 
up extravasated drug carriers in a concentrative manner. It depends on the balance 
of Pout,i vs. Ui whether or not extravasation of circulating drug carriers is accelerated 
by exploiting active targeting techniques. If looks at Eq. 4, one can realize that as 
efflux permeability (Pout,i) is higher, application of active targeting is more 
meaningful. However, it cannot be expected so much. EPR-based medicines 
continue to accumulate slowly into tumor over a few days in spite that their plasma 
concentration gradually decreases. Possible reasons why the tumor uptake did not 
reach plateau within the days include slow vascular efflux permeability, in addition 
to large distribution volume of tumor relative to blood flow. If vascular efflux 
permeability is slow, application of active targeting techniques would not work well, 
as suggested from Eq. 4. In fact, it has been reported that introduction of targeting 
ligands to pegylated nanoparticles sometimes show no effects on pharmacokinetics 
[118] or attenuates their stealth function [119]. On the other hands, if relative 
tumor volume against blood flow is large (that is, tumor tissue is poorly perfused), 
chemotherapy itself is difficult. It has generally been known that tumors 
vasculature is highly irregular and heterogeneous [72; 120]. Insufficient blood 
supply induces nutrient deprivation and subsequently cell cycle arrest. In other 
words, the rate of proliferation of tumor cells is slower in poorly-perfused region 
than in well-perfused region [72; 120]. Tumor cells distally located from blood 
vessels is inevitably resistant to chemotherapeutic agents that target cell 
proliferation [120]. When delivery of the agents to the region is poor, it is extremely 
difficult to kill distal tumor cells.  
 
 
7. Conclusions and future directions 
 
To precisely control drug disposition behavior by the use of drug delivery 
technologies, thorough understandings of pharmacokinetic characteristics at the 
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whole body, organ, and cellular levels are required. Undoubtfully, clearance 
concept-based pharmacokinetic analyses have been contributing to exploring 
biodistribution of macromolecular and particulate drug carriers quantitatively in 
relation to their physicochemical and biological characteristics and developing a 
strategy for rational design of targeted drug delivery system. Ideally, however, 
optimization of therapy should be done based not only on pharmacokinetics but on 
pharmacodynamics. With the progress of molecular 
pharmacokinetics/pharmacodynamics (PK/PD) analyses, PK/PD modeling has been 
developing from a descriptive to a mechanism-based approach. In other words, 
relevant processes on the causal-effect link between drug administration and drug 
effect are recently being considered in PK/PD modeling. Moreover, systems biology 
and systems pharmacology are expected to provide new information on 
identification of multiple targets against complex diseases. Development of drug 
delivery system will, in near future, deal with “when, where and what should be 
delivered”. Therefore, it is essential that fundamental research be carried out to 
address these issues. The future of drug delivery system will depend on rational 
design of nanotechnology materials and methods based on a detailed and thorough 
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Figure 1. Hepatic uptake and urinary excretion clearances of macromolecules in 
mice following intravenous injection. Dex10, dextran (10kDa); Dex70, dextran 
(70kDa); CMDex, carboxymethyl Dex70; DEAEDex, diethylaminoethyl Dex70; IgG, 
immunoglobulin G; BSA, bovine serum albumin; catBSA, cationized BSA; sucBSA, 
succinylated BSA; SOD, superoxide dismutase; CMDexSOD, CMDex-SOD 
conjugate; DEAEDexSOD, DEAEDex-SOD conjugate; pCAT, plasmid DNA encoding 
chloramphenicol acetyltranferase; T10, thymidine decamer. The original data were 
collected from the literatures [61; 87; 121].  
 
Figure 2. Restricted penetration through porous membranes. The ordinate ( 0AA ) 
indicates relative effective area for penetration in porous membranes. The solid and 
broken lines assume the pore radius of 50 nm and 300 nm, respectively. As the 
solute radius increases, steric hindrance becomes larger. The theoretical curves are 
















































where a and r are the solute radius and the pore radius, respectively. 
 
Figure 3. Process of movement from systemic circulation to cell interior. Exraction 
ratio is proportion of single-pass extraction at the steady state, which can be 
calculated from difference between inlet and outlet concentrations. Q, P, and U 
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